AstraZeneca Results Presentation Deck
Scope 1+2 emissions reduction targets
Thousand tonnes tCO₂e
Absolute Scope 1+2 emissions reduction targets
1,600
1,400
1,200
1,000
800
600
400
200
O
AstraZeneca
2015
2020
Sanofi
GSK
Novartis¹
Novo
Nordisk
2025
Pfizer
Merck & Co
Johnson & Johnson
2030
Biogen
AbbVie
2035
Takeda
2040
2045
Roche
2050
Company
AstraZeneca
Novo Nordisk
Takeda
Sanofi
Merck & Co
Roche
Johnson & Johnson
GSK
Biogen
Bayer
Pfizer
AbbVie
Target ranking
Target temperature
alignment (°C) ²
Lonza
Source: Pollination, using Company reports, CDP. Note: Target trajectory is plotted from base year to target year. Actual historical emissions profiles from 2015-2020 will differ. Bayer's target is not displayed due to scale of chart.
Lonza's target is not displayed due to being an intensity target. 1. Novartis' target is to be carbon neutral across Scope 1+2 by 2025 from 2016 base year, level of mitigation targeted is unknown. 2. Utilising the SBTi temperature
36 rating methodology.
* For AstraZeneca Pollination graphed the SBT "reduce absolute scope 1 and 2 GHG emissions 98% by FY2026 from a FY2015 base year"
<1.1
<1.1
<1.1
1.15
1.15
1.24
1.37
1.38
1.39
1.40
1.40
1.64
2.52
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13View entire presentation